Safety and Efficacy Profile of Echinacea purpurea to Prevent Common Cold Episodes: A Randomized, Double-Blind, Placebo-Controlled Trial

M Jawad, R Schoop, A Suter, P Klein, R Eccles, M Jawad, R Schoop, A Suter, P Klein, R Eccles

Abstract

Objective. To investigate the safety (risk) and efficacy (benefit) of Echinacea purpurea extract in the prevention of common cold episodes in a large population over a 4-month period. Methods. 755 healthy subjects were allocated to receive either an alcohol extract from freshly harvested E. purpurea (95% herba and 5% root) or placebo. Participants were required to record adverse events and to rate cold-related issues in a diary throughout the investigation period. Nasal secretions were sampled at acute colds and screened for viruses. Results. A total of 293 adverse events occurred with Echinacea and 306 with placebo treatment. Nine and 10% of participants experienced adverse events, which were at least possibly related to the study drug (adverse drug reactions). Thus, the safety of Echinacea was noninferior to placebo. Echinacea reduced the total number of cold episodes, cumulated episode days within the group, and pain-killer medicated episodes. Echinacea inhibited virally confirmed colds and especially prevented enveloped virus infections (P < 0.05). Echinacea showed maximal effects on recurrent infections, and preventive effects increased with therapy compliance and adherence to the protocol. Conclusions. Compliant prophylactic intake of E. purpurea over a 4-month period appeared to provide a positive risk to benefit ratio.

Figures

Figure 1
Figure 1
Flow diagram of participant disposition.

References

    1. Jackson GG, Dowling HF, Spiesman IG, Boand AV. Transmission of the common cold to volunteers under controlled conditions. I. The common cold as a clinical entity. A.M.A. Archives of Internal Medicine. 1958;101(2):267–278.
    1. Johnston SL. Cromolyns: treatment fo the common cold? Clinical and Experimental Allergy. 1996;26(9):989–994.
    1. Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Archives of Internal Medicine. 2003;163(4):487–494.
    1. Monto AS. Individual and community impact of influenza. PharmacoEconomics. 1999;16(supplement 1):1–6.
    1. Wat D. The common cold: a review of the literature. European Journal of Internal Medicine. 2004;15(2):79–88.
    1. Rotbart HA, Hayden FG. Picornavirus infections: a primer for the practitioner. Archives of Family Medicine. 2000;9(9):913–920.
    1. Johnston SL. Problems and prospects of developing effective therapy for common cold viruses. Trends in Microbiology. 1997;5(2):58–63.
    1. Hendley JO. The host response, not the virus, causes the symptoms of the common cold. Clinical Infectious Diseases. 1998;26(4):847–848.
    1. Jefferson R. Antivirals for the common cold. In: Eccles RWO, editor. Common Cold: Verlag. Basel, Switzerland: Birkhäuser; 2009. pp. 221–236.
    1. Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clinical Infectious Diseases. 2008;46(7):1078–1084.
    1. Grubeck-Loebenstein B, Wick G. The aging of the immune system. Advances in Immunology. 2002;80:243–284.
    1. Bergmann KC. Assessment of the clinical value of using an immunomodulator in recurrent respiratory infections. Advances in Experimental Medicine and Biology. 1995;371:795–797.
    1. Barrett B. Medicinal properties of Echinacea: a critical review. Phytomedicine. 2003;10(1):66–86.
    1. Foster S. Echinacea Nature’s Immune Enhancer. Rochester, Vt, USA: Healing Arts Press; 1991.
    1. Schoeneberger C. The influence of the immunostimulating effects of pressed juice from Echinacea purpurea on the course and severity of cold infections. Forum Immunologie. 1992;8:18–22.
    1. Schmidt UA, Schenk N M. Pflanzliches Immunstimulans senkt Häufigkeit grippaler Infekte. Natur Und GanzheitsMedizin. 1990;3:277–281.
    1. Cohen HA, Varsano I, Kahan E, Sarrell EM, Uziel Y. Effectiveness of an herbal preparation containing Echinacea, propolis, and vitamin C in preventing respiratory tract infections in children: a randomized, double-blind, placebo-controlled, multicenter study. Archives of Pediatrics and Adolescent Medicine. 2004;158(3):217–221.
    1. Melchart D, Walther E, Linde K, Brandmaier R, Lersch C. Echinacea root extracts for the prevention of upper Respiratory tract Infections: a double-blind, placebo-controlled randomized trial. Archives of Family Medicine. 1998;7(6):541–545.
    1. Sperber SJ, Shah LP, Gilbert RD, Ritchey TW, Monto AS. Echinacea purpurea for prevention of experimental rhinovirus colds. Clinical Infectious Diseases. 2004;38(10):1367–1371.
    1. Turner RB, Riker DK, Gangemi JD. Ineffectiveness of Echinacea for prevention of experimental rhinovirus colds. Antimicrobial Agents and Chemotherapy. 2000;44(6):1708–1709.
    1. Turner RB, Bauer R, Woelkart K, Hulsey TC, Gangemi JD. An evaluation of Echinacea angustifolia in experimental rhinovirus infections. The New England Journal of Medicine. 2005;353(4):341–348.
    1. Schoop R, Klein P, Suter A, Johnston SL. Echinacea in the prevention of induced rhinovirus colds: a meta-analysis. Clinical Therapeutics. 2006;28(2):174–183.
    1. Tallarida RJ, Murray RB, Eiben C. A scale for assessing the severity of diseases and adverse drug reactions. Application to drug benefit and risk. Clinical Pharmacology and Therapeutics. 1979;25(4):381–390.
    1. Barrett B, Harahan B, Brown D, Zhang Z, Brown R. Sufficiently important difference for common cold: severity reduction. Annals of Family Medicine. 2007;5(3):216–223.
    1. Barrett B, Endrizzi S, Andreoli P, Barlow S, Zhang Z. Clinical significance of common cold treatment: professionals’ opinions. Wisconsin Medical Journal. 2007;106(8):473–480.
    1. Tiralongo E, Lea RA, Wee SS, Hanna MM, Griffiths LR. Randomised, double blind, placebo-controlled trial of Echinacea supplementation in air travellers. Evidence-Based Complementary and Alternative Medicine. 2012;2012:9 pages.417267
    1. EMEA; EMEA. HMPC. 2008. Community herbal monograph on Echinacea purpurea (L.) moench, herba recens; pp. 1–6.
    1. Rowlands DJ. Rhinoviruses and cells: molecular aspects. American Journal of Respiratory and Critical Care Medicine. 1995;152(4):S31–S35.
    1. Caruso TJ, Gwaltney JM. Treatment of the common cold with Echinacea: a structured review. Clinical Infectious Diseases. 2005;40(6):807–810.
    1. Smith MBH, Feldman W. Over-the-counter cold medications: a critical review of clinical trials between 1950 and 1991. Journal of the American Medical Association. 1993;269(17):2258–2263.
    1. Sharma M, Anderson SA, Schoop R, Hudson JB. Induction of multiple pro-inflammatory cytokines by respiratory viruses and reversal by standardized Echinacea, a potent antiviral herbal extract. Antiviral Research. 2009;83(2):165–170.
    1. Pleschka S, Stein M, Schoop R, Hudson JB. Anti-viral properties and mode of action of standardized Echinacea purpurea extract against highly pathogenic avian Influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV) Virology Journal. 2009;6, article 197

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever